- Home
- VRAR vs ICU Comparison
VRAR vs ICU Comparison
Compare VRAR & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- ICU
- Stock Information
- Founded
- VRAR 2016
- ICU 2018
- Country
- VRAR United States
- ICU United States
- Employees
- VRAR N/A
- ICU N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- ICU Health Care
- Exchange
- VRAR Nasdaq
- ICU Nasdaq
- Market Cap
- VRAR 29.1M
- ICU 25.6M
- IPO Year
- VRAR 2021
- ICU N/A
- Fundamental
- Price
- VRAR $1.55
- ICU $0.87
- Analyst Decision
- VRAR Strong Buy
- ICU
- Analyst Count
- VRAR 1
- ICU 0
- Target Price
- VRAR $2.62
- ICU N/A
- AVG Volume (30 Days)
- VRAR 129.6K
- ICU 1.1M
- Earning Date
- VRAR 11-13-2025
- ICU 11-12-2025
- Dividend Yield
- VRAR N/A
- ICU N/A
- EPS Growth
- VRAR N/A
- ICU N/A
- EPS
- VRAR N/A
- ICU N/A
- Revenue
- VRAR $8,756,789.00
- ICU $766,000.00
- Revenue This Year
- VRAR $23.96
- ICU $894.81
- Revenue Next Year
- VRAR $12.15
- ICU $71.78
- P/E Ratio
- VRAR N/A
- ICU N/A
- Revenue Growth
- VRAR N/A
- ICU N/A
- 52 Week Low
- VRAR $0.50
- ICU $0.31
- 52 Week High
- VRAR $7.00
- ICU $5.34
- Technical
- Relative Strength Index (RSI)
- VRAR 60.95
- ICU 54.67
- Support Level
- VRAR $1.40
- ICU $0.83
- Resistance Level
- VRAR $1.52
- ICU $0.91
- Average True Range (ATR)
- VRAR 0.10
- ICU 0.07
- MACD
- VRAR 0.02
- ICU -0.00
- Stochastic Oscillator
- VRAR 92.00
- ICU 54.45
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.